Dr. Reddy's Laboratories Moat Analysis: Score & Risks
Dr. Reddy's Laboratories Ltd.
A first-pass moat teardown of Dr. Reddy's Laboratories Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow → wide read — primary edge in Network Effects. Provisional, single-pass evidence.
Dr. Reddy's Laboratories Ltd. scores 5.64 on MoatSCORE 6.0 — a narrow → wide moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“We will further scale up in our major markets, which include Russia, China, Brazil, and South Africa and add new geographies by leveraging our in-house global portfolio of generics, peptides and biosimilars”
“Dr. Reddy's became the first company to secure regulatory approval of semaglutide injection for Type 2 Diabetes in Canada, reinforcing our in‑house expertise in peptide science and complex product development.”
“We offer value proposition for our customers through cost leadership, backward integration, reliable customer service and robust compliance track record.”
“The year over year decrease in margins was largely attributable to price erosion in generics segment, particularly in Lenalidomide and lower operating leverage, partly balanced by a better product mix.”
“favourable forex, partially offset by lower volumes in CISR & price erosion in RoW”
“post which it declined, given the pricing challenges in the key US market, slow ramp-up of the Teva portfolio acquired in FY17 (USD350 million), impairments on key products launches during FY20-FY21”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion